New drug added to cancer treatment combo in hopes of boosting immune attack

NCT ID NCT05846646

Terminated Disease control Sponsor: ImmuneSensor Therapeutics Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding an experimental drug called IMSA101 to a standard cancer treatment combination was safe and more effective. The combination included precise radiation therapy and immunotherapy drugs. The trial was for adults with a limited number of cancer metastases from lung or kidney cancer and was terminated early after enrolling only 6 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Baylor College of Medicine Medical Center

Houston, Texas, 77030, United States
City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, 92618, United States
Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, 84112, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Louis Stokes Cleveland VA Medical Center

Cleveland, Ohio, 44106, United States
MetroHealth Medical Center

Cleveland, Ohio, 44109, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
The University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Wisconsin Hospital and Clinics

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.

OLIGOMETASTATIC DISEASE